Core Viewpoint - A class action has been filed against Masonite International Corporation (NYSE: DOOR) for allegedly misleading investors regarding its acquisition by Owens Corning's Doors, particularly concerning undisclosed offers and share repurchases [1] Group 1: Allegations and Misconduct - The class action arises from claims that Masonite made material omissions and misrepresentations about Owens Corning's offers to purchase all outstanding common stock at significant premiums [1] - Masonite repurchased nearly 270,000 shares for approximately $25 million between June 2023 and December 2023, while failing to disclose Owens Corning's offers for about eight months [1] - During the class period, Masonite made misleading statements about its share buyback activities, claiming they were meant to distribute capital back to investors without disclosing the higher offers from Owens Corning [1] Group 2: Stock Price Impact - Following the announcement of the arrangement agreement on February 9, 2024, Masonite's stock price surged to $130.51, reflecting a 35.1% increase from the previous trading day's close [1] Group 3: Legal Proceedings - Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by April 7, 2026, and participation is not required to be eligible for recovery [1] - Robbins LLP, the firm leading the class action, operates on a contingency fee basis, meaning shareholders incur no fees or expenses [1]

Core Viewpoint - A class action has been filed against Inovio Pharmaceuticals, Inc. for allegedly misleading investors regarding the approval process for its CELLECTRA device and the INO-3107 Biologics License Application (BLA) [1] Group 1: Allegations and Issues - The complaint alleges that Inovio failed to disclose deficiencies in the manufacturing of its CELLECTRA device [1] - It is claimed that Inovio was unlikely to submit the INO-3107 BLA to the FDA by the second half of 2024 due to these manufacturing issues [1] - The company reportedly lacked sufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review [1] Group 2: Impact on Stock Price - Following a press release on August 8, 2024, revealing a delay in the INO-3107 BLA submission to mid-2025, Inovio's stock price fell by $0.27 per share, or 3.1%, closing at $8.44 per share on August 9, 2024 [1] - On December 29, 2025, after announcing that the FDA accepted the INO-3107 BLA on a standard review timeline, Inovio's stock price dropped by $0.56 per share, or 24.45%, closing at $1.73 per share [1] Group 3: Class Action Participation - Shareholders may be eligible to participate in the class action against Inovio, with a deadline to submit papers to the court by April 7, 2026 [1] - The lead plaintiff will represent other class members in directing the litigation, but participation is not required for recovery [1]

Core Viewpoint - A class action has been filed against Paysafe Limited (NYSE: PSFE) on behalf of investors who acquired its securities between March 4, 2025, and November 12, 2025, due to allegations of misleading information regarding its business prospects [1][2]. Group 1: Allegations - The complaint alleges that Paysafe failed to disclose significant exposure to a high-risk client in its ecommerce business [2] - It is claimed that the company's credit loss reserves and/or write-offs were understated as a result of this exposure [2] - The company reportedly had undisclosed issues with higher risk Merchant Category Codes, complicating its client services [2] - These issues were likely to negatively impact the company's revenue growth and overall revenue mix [2] - Consequently, Paysafe was unlikely to meet its previously issued financial guidance for fiscal year 2025 [2] Group 2: Stock Price Impact - Following the revelation of these issues, Paysafe's stock price dropped by $2.80, or 27.6%, closing at $7.36 per share on November 13, 2025 [3] Group 3: Class Action Participation - Shareholders interested in serving as lead plaintiff must submit their papers to the court by April 7, 2026 [4] - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4] Group 4: Legal Representation - All representation in this matter is on a contingency fee basis, meaning shareholders incur no fees or expenses [5]

Company Overview - Kyndryl is a provider of information technology infrastructure services [2] Recent Developments - On February 9, 2026, Kyndryl announced that its Audit Committee is reviewing cash management practices and related disclosures, including the drivers of the Company's adjusted free cash flow metric, following requests from the SEC [3] - The review has delayed the finalization of the Quarterly Report and the assessment of internal control over financial reporting [3] - Key executive departures were reported, including David Wyshner as Chief Financial Officer and Edward Sebold as General Counsel, effective immediately [3] - Vineet Khurana also stepped down from his position as Senior Vice President and Global Controller, taking on a different role within the Company [3] - Following these announcements, Kyndryl's stock price fell nearly 55% [3]

Core Viewpoint - A class action has been filed against Mereo BioPharma Group plc for allegedly misleading investors regarding the Phase 3 ORBIT and COSMIC studies for setrusumab, which did not meet their primary endpoints [2][3] Group 1: Allegations and Misleading Information - The complaint alleges that Mereo BioPharma provided investors with overly optimistic statements about the expected results of the Phase 3 ORBIT and COSMIC studies, claiming confidence in setrusumab's ability to reduce annualized fracture rates [2] - It is claimed that while making these positive statements, Mereo concealed material adverse facts about the true state of the Phase 3 studies, which ultimately did not achieve their primary endpoints [2] - The studies failed to show a reduction in annualized clinical fracture rates compared to placebo or bisphosphonate control groups, leading to artificially inflated prices for Mereo's American Depository Shares (ADS) [2] Group 2: Impact of the Announcement - On December 29, 2025, Mereo announced that neither the ORBIT nor the COSMIC studies met their primary endpoint, resulting in a significant decline in the price of Mereo's ADS from $2.31 to $0.29, a drop of over 87.7% [3] Group 3: Class Action Participation - Shareholders may be eligible to participate in the class action against Mereo BioPharma, with a deadline to submit papers to serve as lead plaintiff by April 6, 2026 [4] - Shareholders do not need to participate in the case to be eligible for recovery and can remain absent class members if they choose [4]

Core Viewpoint - A class action has been filed against Ultragenyx Pharmaceutical Inc. for allegedly misleading investors regarding the Phase III Orbit and Cosmic Studies for setrusumab, which tested its efficacy in treating Osteogenesis Imperfecta [1][2]. Group 1: Allegations and Misleading Information - The complaint alleges that Ultragenyx provided overly positive statements about setrusumab's expected results, claiming it would decrease the annualized fracture rate in patients with Osteogenesis Imperfecta [2]. - Defendants are accused of concealing material adverse facts about setrusumab's potential and the risks associated with the study protocols, specifically that while setrusumab increases bone density, it does not correlate with a decrease in fracture rates [3]. Group 2: Study Results and Stock Impact - On December 29, 2025, Ultragenyx announced that the Phase III Orbit and Cosmic Studies did not achieve statistical significance in reducing the annualized clinical fracture rate compared to placebo or bisphosphonates [4]. - Following this announcement, Ultragenyx's stock price plummeted from $34.19 per share on December 26, 2025, to $19.72 per share on December 29, 2025, marking a decline of approximately 42.32% in one day [4]. Group 3: Class Action Participation - Shareholders may be eligible to participate in the class action against Ultragenyx and can contact Robbins LLP if they wish to serve as lead plaintiff [5]. - Shareholders do not need to participate in the case to be eligible for recovery and can remain absent class members if they choose [5].

Core Viewpoint - A class action has been filed against Inovio Pharmaceuticals, Inc. for allegedly misleading investors regarding the approval process of its CELLECTRA device and the INO-3107 Biologics License Application (BLA) [1][2]. Group 1: Allegations and Issues - Robbins LLP is investigating claims that Inovio misled investors by failing to disclose deficiencies in the manufacturing of the CELLECTRA device, which impacted the timeline for submitting the INO-3107 BLA to the FDA [2]. - The complaint states that Inovio was unlikely to submit the INO-3107 BLA by the second half of 2024 due to these manufacturing issues and lacked sufficient information to justify eligibility for FDA accelerated approval [2]. - The overall regulatory and commercial prospects of INO-3107 were allegedly overstated by the company [2]. Group 2: Stock Price Impact - Following a press release on August 8, 2024, revealing a delay in the submission timeline for the INO-3107 BLA to mid-2025, Inovio's stock price fell by $0.27 per share, or 3.1%, closing at $8.44 on August 9, 2024 [3]. - On December 29, 2025, after announcing that the FDA accepted the INO-3107 BLA on a standard review timeline rather than an accelerated one, Inovio's stock price dropped by $0.56 per share, or 24.45%, closing at $1.73 [4]. Group 3: Class Action Participation - Shareholders may be eligible to participate in the class action against Inovio Pharmaceuticals and can contact Robbins LLP if they wish to serve as lead plaintiff [5]. - Shareholders do not need to participate in the case to be eligible for recovery and can remain absent class members if they choose [5].

Core Viewpoint - A class action has been filed against Ramaco Resources, Inc. for allegedly overstating development progress at its Brook Mine, with claims that no significant mining activity has occurred since its groundbreaking [1][2]. Group 1: Allegations and Investigations - Robbins LLP is investigating allegations that Ramaco Resources, Inc. failed to disclose the lack of significant mining activity at the Brook Mine after its groundbreaking [2]. - A report by Wolfpack Research claims that the Brook Mine is a "hoax" and that no active mining has taken place, supported by drone footage showing no work occurring three months post-groundbreaking [3]. - Following the report, Ramaco's stock price dropped by $3.81, or 9.6%, closing at $36.01 per share on October 23, 2025 [3]. Group 2: Class Action Participation - Shareholders may be eligible to participate in the class action against Ramaco Resources, Inc., with options to serve as lead plaintiff or remain an absent class member [4]. - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses for participation [5].

Core Viewpoint - A class action lawsuit has been filed against Mereo BioPharma Group plc, alleging that the company misled investors regarding the results of its Phase 3 studies for setrusumab, which did not meet primary endpoints, leading to significant stock price decline [1] Group 1: Allegations and Misleading Information - The lawsuit claims that Mereo BioPharma provided investors with overly optimistic statements about the Phase 3 ORBIT and COSMIC studies for setrusumab, suggesting confidence in its efficacy in reducing annualized fracture rates [1] - It is alleged that while making positive statements, Mereo concealed material adverse facts about the true state of the Phase 3 programs, which ultimately did not achieve their primary endpoints [1] Group 2: Impact on Stock Price - Following the announcement on December 29, 2025, that neither the ORBIT nor COSMIC studies met their primary endpoints, Mereo's American Depository Shares (ADS) plummeted from $2.31 to $0.29, representing a decline of over 87.7% [1]

Core Viewpoint - A class action has been filed against BlackRock TCP Capital Corp. for allegedly misleading investors regarding its business prospects and financial health during a specified period [1][2]. Group 1: Allegations - The complaint alleges that BlackRock TCP failed to disclose that its investments were not being timely or appropriately valued [2] - It is claimed that the company's portfolio restructuring efforts were ineffective in resolving challenged credits or improving portfolio quality [2] - The company's unrealized losses were reportedly understated, leading to an overstated Net Asset Value (NAV) [2] - Positive statements made by the defendants about the company's business and prospects were deemed materially misleading [2] Group 2: Financial Disclosure - On January 23, 2026, BlackRock TCP disclosed that its NAV per share as of December 31, 2025, was between $7.05 and $7.09, which is 19% lower than the previous quarter and 23.4% lower than the previous year [3] - Following this disclosure, the stock price fell by $0.76, or 12.97%, closing at $5.10 per share on January 26, 2026 [3] Group 3: Class Action Participation - Shareholders interested in serving as lead plaintiffs must file their papers with the court by April 6, 2026 [4] - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4]